Clark Mitchall G. 4

4 · Atara Biotherapeutics, Inc. · Filed Mar 28, 2018

Insider Transaction Report

Form 4

Period: 2018-03-27

Atara Biotherapeutics, Inc.ATRA

Clark Mitchall G.

Chief R & QA Officer

Transactions

Sale
Common Stock
2018-03-27$38.23/sh−29,980$1,146,135→ 172,144 total
Sale
Common Stock
2018-03-27$41.10/sh−11,103$456,333→ 156,071 total
Exercise/Conversion
Employee Stock Option (Right to Buy)
2018-03-27−28,848→ 11,194 total
Exercise: $25.15Exp: 2022-01-16→ Common Stock (28,848 underlying)
Exercise/Conversion
Common Stock
2018-03-27$22.72/sh+32,500$738,400→ 244,868 total
Sale
Common Stock
2018-03-27$36.43/sh−22,794$830,385→ 233,480 total
Exercise/Conversion
Common Stock
2018-03-27$25.15/sh+28,848$725,527→ 212,368 total
Exercise/Conversion
Common Stock
2018-03-27$11.00/sh+11,406$125,466→ 256,274 total
Sale
Common Stock
2018-03-27$39.53/sh−2,170$85,780→ 169,974 total
Sale
Common Stock
2018-03-27$40.40/sh−2,800$113,120→ 167,174 total
Exercise/Conversion
Employee Stock Option (Right to Buy)
2018-03-27−11,406→ 3,125 total
Exercise: $11.00Exp: 2021-10-14→ Common Stock (11,406 underlying)
Sale
Common Stock
2018-03-27$37.10/sh−31,356$1,163,308→ 202,124 total
Exercise/Conversion
Employee Stock Option (Right to Buy)
2018-03-27−32,500→ 32,500 total
Exercise: $22.72Exp: 2022-12-17→ Common Stock (32,500 underlying)

Footnotes (9)

[F1]Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018.
[F2]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $35.70 to $36.70. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F3]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $36.75 to $37.75. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F4]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $37.80 to $38.80. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F5]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.85 to $39.75. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F6]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.00 to $40.65. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F7]1/48th of the shares subject to the stock option vest and become exercisable each month following January 16, 2015.
[F8]1/48th of the shares subject to the stock option vest and become exercisable each month following December 17, 2015.
[F9]1/48th of the shares subject to the stock option vest and become exercisable each month following October 15, 2014.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION